Hospital
Vernon Memorial Healthcare, INC.
Vernon Memorial Healthcare, INC. was paid $9.01M by Medicaid between Jan 2018 and Dec 2024, across 161 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 15% of everything it billed.
33Billing provider infoVERNON MEMORIAL HEALTHCARE, INC.
VIROQUA, WI 54665
VIROQUA, WI 54665
33aNPI1497750921assigned 06/21/2005
33bProvider typeCritical Access Hospital
28Total paid$9.01M
24GClaims250,278
24DCodes billed161
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#12 of 48
Median peer was paid$4.30M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,763 | $981K | |
| 2019 | 29,113 | $953K | |
| 2020 | 26,672 | $1.03M | |
| 2021 | 40,009 | $1.54M | |
| 2022 | 42,630 | $1.47M | |
| 2023 | 42,364 | $1.60M | |
| 2024incomplete | 35,727 | $1.43M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 3,327 | 2,583 | $1.35M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9.2% | 5,001 | 4,219 | $825K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 8.8% | 3,667 | 2,583 | $790K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.9% | 5,693 | 4,942 | $535K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.9% | 2,698 | 1,726 | $531K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 5.9% | 2,804 | 2,468 | $527K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 2,213 | 1,579 | $495K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.4% | 6,474 | 5,300 | $487K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 5.3% | 1,681 | 1,213 | $476K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.1% | 5,068 | 3,834 | $277K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.1% | 5,544 | 4,355 | $276K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.1% | 993 | 846 | $189K |
149 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 2,365 | $144K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 7,398 | $142K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 1,695 | $135K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 2,653 | $96K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,451 | $86K |
| 80053 | Comprehensive metabolic panel | <1% | 10,230 | $74K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 930 | $73K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,382 | $73K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,555 | $61K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,315 | $60K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,207 | $60K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 183 | $59K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,974 | $47K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 201 | $45K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 935 | $44K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,585 | $42K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 119 | $41K |
| 73630 | <1% | 997 | $39K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 179 | $35K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 594 | $35K |
| 36000 | <1% | 492 | $33K | |
| 80061 | Lipid panel | <1% | 2,127 | $31K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,957 | $30K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,088 | $29K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 846 | $28K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 855 | $28K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 13 | $26K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,776 | $25K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,348 | $25K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,849 | $25K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,660 | $24K |
| 84484 | <1% | 5,769 | $23K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,617 | $22K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 606 | $22K |
| 97162 | <1% | 485 | $19K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 426 | $18K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 1,128 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,016 | $16K |
| 81025 | <1% | 1,863 | $15K | |
| 73562 | <1% | 404 | $14K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 95 | $14K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 271 | $13K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 331 | $13K |
| 83690 | <1% | 3,160 | $12K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,972 | $12K |
| 81001 | <1% | 5,511 | $12K | |
| 83735 | <1% | 3,812 | $12K | |
| G0378 | Hospital observation service, per hour | <1% | 694 | $11K |
| 82805 | <1% | 886 | $11K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 166 | $10K |
| 87077 | <1% | 1,828 | $10K | |
| 87040 | <1% | 3,056 | $10K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,451 | $9K |
| 85379 | <1% | 1,980 | $9K | |
| 73502 | <1% | 306 | $9K | |
| 83880 | <1% | 934 | $9K | |
| 83605 | <1% | 2,358 | $9K | |
| 73610 | <1% | 292 | $8K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 327 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,463 | $8K |
| 85610 | <1% | 2,431 | $8K | |
| 84145 | <1% | 1,045 | $8K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 111 | $8K |
| 84439 | <1% | 951 | $8K | |
| 87186 | <1% | 1,708 | $8K | |
| 86618 | <1% | 558 | $7K | |
| 81003 | <1% | 3,465 | $7K | |
| 82565 | <1% | 1,718 | $7K | |
| 86140 | <1% | 1,983 | $6K | |
| 84460 | <1% | 1,874 | $6K | |
| 82728 | <1% | 537 | $6K | |
| 80047 | <1% | 473 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 304 | $5K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 188 | $4K |
| 73030 | <1% | 185 | $4K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 18 | $4K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,304 | $4K |
| 96367 | <1% | 34 | $4K | |
| 84450 | <1% | 1,304 | $4K | |
| 85027 | <1% | 1,041 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,320 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 231 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,835 | $3K |
| 82962 | <1% | 1,983 | $3K | |
| 82947 | <1% | 717 | $3K | |
| 82247 | <1% | 1,213 | $3K | |
| 82040 | <1% | 968 | $3K | |
| 97113 | <1% | 77 | $3K | |
| 84075 | <1% | 1,079 | $2K | |
| 80050 | General health panel | <1% | 167 | $2K |
| 84703 | <1% | 329 | $2K | |
| 82077 | <1% | 229 | $2K | |
| 73130 | <1% | 54 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 68 | $2K |
| 73110 | <1% | 45 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,957 | $2K |
| 82248 | <1% | 840 | $2K | |
| 82803 | <1% | 182 | $2K | |
| 80306 | <1% | 114 | $1K | |
| 85652 | <1% | 681 | $1K | |
| 96376 | <1% | 552 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 115 | $1K |
| 74018 | <1% | 56 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 23 | $1K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 28 | $958.20 |
| 82607 | <1% | 69 | $908.75 | |
| 97161 | <1% | 14 | $751.92 | |
| 99201 | <1% | 15 | $698.84 | |
| 85018 | <1% | 376 | $696.19 | |
| 83550 | <1% | 126 | $686.28 | |
| 86580 | <1% | 34 | $657.94 | |
| 87210 | <1% | 104 | $568.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 34 | $536.80 |
| 83540 | <1% | 126 | $508.44 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 586 | $486.65 |
| 73560 | <1% | 21 | $454.69 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,686 | $343.07 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,851 | $334.33 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 939 | $258.22 |
| 77073 | <1% | 15 | $250.56 | |
| 97163 | <1% | 28 | $243.33 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 788 | $222.69 |
| 83655 | <1% | 14 | $175.14 | |
| 86703 | <1% | 12 | $170.04 | |
| 86850 | <1% | 56 | $166.61 | |
| 86900 | <1% | 48 | $162.34 | |
| 80051 | <1% | 40 | $150.01 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,235 | $134.10 |
| J2704 | Injection, propofol, 10 mg | <1% | 686 | $104.06 |
| 82043 | <1% | 15 | $91.70 | |
| 86901 | <1% | 49 | $77.25 | |
| 94761 | <1% | 479 | $41.86 | |
| 85730 | <1% | 20 | $37.26 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,505 | $17.36 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 67 | $3.55 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 30 | $2.05 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 34 | $1.96 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 32 | $1.36 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 229 | $0.59 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 165 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 69 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 33 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 80 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 18 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 65 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 12 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 15 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARTBERG, DAVID (CEO)
| Provider | Location | Paid |
|---|---|---|
| Vernon Memorial Healthcare, INC | Viroqua, WI | $692K |
| Vernon Memorial Healthcare, INC. | La Farge, WI | $233K |
| Vernon Memorial Healthcare, INC. | Soldiers Grove, WI | $43K |
| Vernon Memorial Healthcare, INC. | Westby, WI | $41K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.